Smart ring maker Oura postpones its anticipated $2.2B initial public offering (IPO) citing broader market uncertainty, keeping the wearable health technology leader private! KEY HIGHLIGHTS: • Pharma giant Eli Lilly $LLY planned a $100M strategic investment to back Oura's projected 90% revenue growth trajectory • Lead IPO underwriters Goldman Sachs $GS, Morgan Stanley $MS, and JPMorgan $JPM all currently carry a Seeking Alpha Quant rating of HOLD • Oura's IPO delay keeps it private as it competes directly against Apple $AAPL in wearables, where Apple maintains an A+ Profitability Factor Grade THE RATING: Eli Lilly $LLY leads the group with a staggering 50% revenue growth rate, dwarfing Goldman Sachs $GS ( 23%) and Apple $AAPL (14.2%), while underwriters $GS, $MS, and $JPM all sit at a Quant HOLD. Do you think Oura delaying its $2.2B IPO is a smart tactical move to wait out market volatility, or will Apple $AAPL continue to dominate wearable health tech in the meantime? Drop your take below! ▻